文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

超声内镜引导下胆道引流作为首选方案使用腔壁贴合金属支架对比内镜逆行胰胆管造影治疗恶性远端胆道梗阻:多中心随机对照研究(ELEMENT试验)

Endoscopic Ultrasound-Guided Biliary Drainage of First Intent With a Lumen-Apposing Metal Stent vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Study (ELEMENT Trial).
PubMed 文献 · Gastroenterology · 2023-08-06

这项多中心随机对照试验在加拿大10家和法国1家机构纳入144例恶性远端胆道梗阻患者,比较超声内镜引导下胆管十二指肠吻合术(EUS-CDS)与内镜逆行胰胆管造影联合金属支架置入(ERCP-M)。EUS-CDS组手术时间更短,技术成功率非劣效,1年支架功能障碍率两组无差异。结论认为EUS-CDS是有效安全的替代方案,但支架功能未显示优效。

要点

  • EUS-CDS平均手术时间14.0分钟,ERCP-M为23.1分钟(P < .01)。
  • 技术成功率EUS-CDS 90.4% vs ERCP-M 83.1%,风险差7.3%提示非劣效。
  • 1年支架功能障碍率EUS-CDS 9.6% vs ERCP-M 9.9%(P = .96),无显著差异。

核心结论

  • EUS-CDS在支架功能上未显示优效,但在恶性远端胆道梗阻患者中是ERCP-M的有效且安全的替代方案。
  • 这些发现为EUS-CDS作为ERCP的互补和可互换一线方式在临床实践中更广泛采用提供了证据。

研究设计与样本

  • 多中心随机对照试验,在加拿大10家机构和法国1家机构招募患者。
  • 纳入继发于临界可切除、局部晚期或不可切除壶腹周围癌的恶性远端胆道梗阻患者。
  • 优效性试验,同时评估技术成功的非劣效性;按意向性治疗原则分析。
  • 2019年2月至2022年2月共招募144例患者,EUS-CDS组73例,ERCP-M组71例。

主要发现

  • 平均(SD)手术时间EUS-CDS组14.0(11.4)分钟 vs ERCP-M组23.1(15.6)分钟(P < .01);EUS-CDS组40%未使用透视。
  • 技术成功率EUS-CDS组90.4%(95% CI,81.5%至95.3%) vs ERCP-M组83.1%(95% CI,72.7%至90.1%),风险差7.3%(95% CI,-4.0%至18.8%),提示非劣效。
  • 支架功能障碍发生率EUS-CDS组9.6% vs ERCP-M组9.9%(P = .96)。
  • 不良事件、胰十二指肠切除术及肿瘤学结局或生活质量方面未见差异。

关键数值与推荐

  • 主要终点为1年时支架功能障碍率,考虑死亡、临床失败和手术切除的竞争风险。

临床怎么用

  • 作者结论认为EUS-CDS是恶性远端胆道梗阻患者中ERCP-M的有效且安全的替代方案。
  • 作者认为这些发现为EUS-CDS作为ERCP的互补和可互换一线方式在临床实践中更广泛采用提供了证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic ultrasound-guided choledochoduodenostomy with a lumen-apposing metal stent (EUS-CDS) is a promising modality for management of malignant distal biliary obstruction (MDBO) with potential for better stent patency. We compared its outcomes with endoscopic retrograde cholangiopancreatography with metal stenting (ERCP-M). METHODS: In this multicenter randomized controlled trial, we recruited patients with MDBO secondary to borderline resectable, locally advanced, or unresectable peri-ampullary cancers across 10 Canadian institutions and 1 French institution. This was a superiority trial with a noninferiority assessment of technical success. Patients were randomized to EUS-CDS or ERCP-M. The primary end point was the rate of stent dysfunction at 1 year, considering competing risks of death, clinical failure, and surgical resection. Analyses were performed according to intention-to-treat principles. RESULTS: From February 2019 to February 2022, 144 patients were recruited; 73 were randomized to EUS-CDS and 71 were randomized to ERCP-M. The mean (SD) procedure time was 14.0 (11.4) minutes for EUS-CDS and 23.1 (15.6) minutes for ERCP-M (P < .01); 40% of the former was performed without fluoroscopy. Technical success was achieved in 90.4% (95% CI, 81.5% to 95.3%) of EUS-CDS and 83.1% (95% CI, 72.7% to 90.1%) of ERCP-M with a risk difference of 7.3% (95% CI, -4.0% to 18.8%) indicating noninferiority. Stent dysfunction occurred in 9.6% vs 9.9% of EUS-CDS and ERCP-M cases, respectively (P = .96). No differences in adverse events, pancreaticoduodenectomy and oncologic outcomes, or quality of life were noted. CONCLUSIONS: Although not superior in stent function, EUS-CDS is an efficient and safe alternative to ERCP-M in patients with MDBO. These findings provide evidence for greater adoption of EUS-CDS in clinical practice as a complementary and exchangeable first-line modality to ERCP in patients with MDBO. CLINICALTRIALS: gov, Number: NCT03870386.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen YI, Sahai A, Donatelli G, et al. Endoscopic Ultrasound-Guided Biliary Drainage of First Intent With a Lumen-Apposing Metal Stent vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Study (ELEMENT Trial). Gastroenterology. 2023. PMID: 37549753. doi:10.1053/j.gastro.2023.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。